Cargando…

Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review

Huntington disease is an autosomal dominant inherited brain disorder that typically becomes manifest in adulthood. Juvenile‐onset Huntington disease refers to approximately 5% of patients with symptom onset before the age of 21 years. The causal factor is a pathologically expanded CAG repeat in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bakels, Hannah S., Roos, Raymund A.C., van Roon‐Mom, Willeke M.C., de Bot, Susanne T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291924/ https://www.ncbi.nlm.nih.gov/pubmed/34636452 http://dx.doi.org/10.1002/mds.28823

Ejemplares similares

Post‐mortem 7T MR imaging and neuropathology in middle stage juvenile‐onset Huntington disease: A case report
por: Bakels, Hannah S., et al.
Publicado: (2022)

Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset
por: Gardiner, Sarah L., et al.
Publicado: (2018)

GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study
por: Tramutola, Antonella, et al.
Publicado: (2023)

Making (anti-) sense out of huntingtin levels in Huntington disease
por: Evers, Melvin M, et al.
Publicado: (2015)

Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood
por: Mastrokolias, Anastasios, et al.
Publicado: (2015)

Pathological characterization of T2*-weighted MRI contrast in the striatum of Huntington’s disease patients
por: Bulk, Marjolein, et al.
Publicado: (2020)

Machine learning in Huntington’s disease: exploring the Enroll-HD dataset for prognosis and driving capability prediction
por: Ouwerkerk, Jasper, et al.
Publicado: (2023)

The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
por: Heinz, Annika, et al.
Publicado: (2021)

Common disease signatures from gene expression analysis in Huntington’s disease human blood and brain
por: Mina, Eleni, et al.
Publicado: (2016)

Cortical neurodevelopment in pre-manifest Huntington's disease
por: Kubera, Katharina M., et al.
Publicado: (2019)

Early grey matter changes in structural covariance networks in Huntington's disease
por: Coppen, Emma M., et al.
Publicado: (2016)

Dynamics of the connectome in Huntington's disease: A longitudinal diffusion MRI study
por: Odish, Omar F.F., et al.
Publicado: (2015)

Hypertension, Antihypertensive Use and the Delayed‐Onset of Huntington's Disease
por: Steventon, Jessica J., et al.
Publicado: (2020)

More than a co-incidence? Comment on: Amyotrophic lateral sclerosis is over‐represented in two Huntington’s disease brain bank cohorts: further evidence to support genetic pleiotropy of pathogenic HTT gene expansion
por: Bakels, Hannah S., et al.
Publicado: (2022)

Huntington's disease: a clinical review
por: Roos, Raymund AC
Publicado: (2010)

Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease
por: van Roon-Mom, Willeke MC, et al.
Publicado: (2008)

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
por: Synofzik, Matthis, et al.
Publicado: (2022)

Aspiration pneumonia and death in Huntington’s disease
por: Heemskerk, Anne-Wil, et al.
Publicado: (2012)

The Many Faces of Huntington’s Chorea Treatment: The Impact of Sudden Withdrawal of Tiapride after 40 Years of Use and a Systematic Review
por: Feleus, Stephanie, et al.
Publicado: (2022)

Statistical method for modeling sequencing data from different technologies in longitudinal studies with application to Huntington disease
por: Fuady, Angga M., et al.
Publicado: (2020)

Disease Onset in Huntington's Disease: When Is the Conversion?
por: Oosterloo, Mayke, et al.
Publicado: (2021)

Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study
por: Baake, Verena, et al.
Publicado: (2018)

Special Issue: Juvenile Onset Huntington’s Disease
por: Nopoulos, Peg C.
Publicado: (2020)

Diagnosing Juvenile Huntington’s Disease: An Explorative Study among Caregivers of Affected Children
por: Oosterloo, Mayke, et al.
Publicado: (2020)

Autonomic Changes in Juvenile-Onset Huntington’s Disease
por: Schultz, Jordan L., et al.
Publicado: (2020)

Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington’s disease peripheral blood samples
por: Mastrokolias, Anastasios, et al.
Publicado: (2016)

Cystathionine Levels in Patients With Huntington Disease
por: Aziz, N.A., et al.
Publicado: (2015)

The dynamics of early-state transcriptional changes and aggregate formation in a Huntington’s disease cell model
por: van Hagen, Martijn, et al.
Publicado: (2017)

Behavioral Deficits in Juvenile Onset Huntington’s Disease
por: Langbehn, Kathleen E., et al.
Publicado: (2020)

Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children
por: Byrne, Lauren M., et al.
Publicado: (2022)

Reduced functional brain connectivity prior to and after disease onset in Huntington's disease()()
por: Dumas, Eve M., et al.
Publicado: (2013)

Brain structure in juvenile-onset Huntington disease
por: Tereshchenko, Alexander, et al.
Publicado: (2019)

Co-expression Patterns between ATN1 and ATXN2 Coincide with Brain Regions Affected in Huntington’s Disease
por: Keo, Arlin, et al.
Publicado: (2017)

Delayed onset of the diurnal melatonin rise in patients with Huntington’s disease
por: Aziz, N. Ahmad, et al.
Publicado: (2009)

Study protocol of the HD-MED study aiming to personalize drug treatment in Huntington’s disease: a longitudinal, observational study to assess medication use and efficacy in relation to pharmacogenetics
por: Feleus, Stephanie, et al.
Publicado: (2023)

Atrophy of the putamen at time of clinical motor onset in Huntington’s disease: a 6-year follow-up study
por: Coppen, Emma M., et al.
Publicado: (2018)

Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington’s disease
por: van de Zande, Nadine Anniek, et al.
Publicado: (2023)

Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in Huntington's disease
por: Vittori, Angelica, et al.
Publicado: (2014)

Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease
por: Stoker, Thomas B., et al.
Publicado: (2020)

Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials
por: Langbehn, Douglas R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ar7oes5v0nbddtac716o99efjv